2024
Maternal Bereavement and Heart Failure Risk of the Offspring
Goldstein S, Pastor T, Samsky M. Maternal Bereavement and Heart Failure Risk of the Offspring. JACC Heart Failure 2024, 12: 1363-1364. PMID: 39111951, DOI: 10.1016/j.jchf.2024.06.002.Peer-Reviewed Original ResearchThe management of heart failure cardiogenic shock: an international RAND appropriateness panel
Williams S, Kalakoutas A, Olusanya S, Schrage B, Tavazzi G, Carnicelli A, Montero S, Vandenbriele C, Luk A, Lim H, Bhagra S, Ott S, Farrero M, Samsky M, Kennedy J, Sen S, Agrawal R, Rampersad P, Coniglio A, Pappalardo F, Barnett C, Proudfoot A. The management of heart failure cardiogenic shock: an international RAND appropriateness panel. Critical Care 2024, 28: 105. PMID: 38566212, PMCID: PMC10988801, DOI: 10.1186/s13054-024-04884-5.Peer-Reviewed Original ResearchConceptsTemporary mechanical circulatory supportClinical practiceHF-CSCritical care admissionMulti-disciplinary panelRandomised controlled trialsClinical guidelinesAcutely decompensated chronic HFBackgroundObservational dataControlled trialsDecompensated chronic HFAppropriate methodologiesTrial designInternational expertsConclusionThis studyClinical trial designMechanical circulatory supportChronic HFCardiogenic shockClinical trialsAppropriate panelThoracic ultrasoundCirculatory supportLos AngelesPractice
2023
Electronic Health Record Embedded Strategies for Improving Care of Patients With Heart Failure
Fuery M, Kadhim B, Samsky M, Freeman J, Clark K, Desai N, Wilson F, Ahmed T, Ahmad T. Electronic Health Record Embedded Strategies for Improving Care of Patients With Heart Failure. Current Heart Failure Reports 2023, 20: 280-286. PMID: 37552356, DOI: 10.1007/s11897-023-00614-0.Peer-Reviewed Original ResearchConceptsHeart failure patientsFailure patientsElectronic health recordsEHR alertClinical trialsRandomized clinical trialsCare of patientsQuality of careHeart failureClinician satisfactionRandomized fashionRecent FindingsTherePatientsUnmet needPatient careClinical decisionEvidence-based decisionsFuture interventionsCareHealth recordsTrialsCliniciansInterventionFindingsThereRisk Prediction for Heart Failure Patients Admitted to the Intensive Care Unit Insights From REVeAL-HF
O’Connor K, Yamamoto Y, Sen S, Samsky M, Wilson F, Desai N, Ahmad T, Fuery M. Risk Prediction for Heart Failure Patients Admitted to the Intensive Care Unit Insights From REVeAL-HF. JACC Heart Failure 2023, 11: 727-728. PMID: 37052546, DOI: 10.1016/j.jchf.2023.01.021.Peer-Reviewed Original Research
2022
Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial
Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAcute heart failureHeart failurePragmatic trialElectronic health recordsSubstantial health care costsBest practice advisoryReduced ejection fractionUsual care armHealth recordsTime of dischargeEvidence-based careHealth care costsClinical decision support systemAHF patientsCare armEligible patientsHF hospitalizationInpatient initiationCardiovascular deathMedication classesEjection fractionMedical therapyPrimary outcomePractice advisoryNetwork Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trialsSacubitril/Valsartan in Advanced Heart Failure Shattering the Paradigm to Focus on Real LIFE ∗
Samsky MD, Sen S. Sacubitril/Valsartan in Advanced Heart Failure Shattering the Paradigm to Focus on Real LIFE ∗. JACC Heart Failure 2022, 10: 457-458. PMID: 35772854, DOI: 10.1016/j.jchf.2022.05.011.Commentaries, Editorials and Letters
2021
Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction
Greene SJ, Choi S, Lippmann SJ, Mentz RJ, Greiner MA, Hardy NC, Hammill BG, Luo N, Samsky MD, Heidenreich PA, Laskey WK, Yancy CW, Peterson PN, Curtis LH, Hernandez AF, Fonarow GC, O'Brien EC. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Journal Of The American Heart Association 2021, 10: e021459. PMID: 34350772, PMCID: PMC8475054, DOI: 10.1161/jaha.121.021459.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAminobutyratesAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundsDrug CombinationsFemaleHeart FailureHospitalizationHumansMaleMedicareNeprilysinPatient DischargeProtease InhibitorsRegistriesRisk AssessmentRisk FactorsStroke VolumeTime FactorsTreatment OutcomeUnited StatesValsartanVentricular Function, LeftConceptsEnzyme inhibitors/angiotensin II receptor blockersSacubitril/valsartanAngiotensin II receptor blockersII receptor blockersHeart failure hospitalizationReduced ejection fractionCause hospitalizationReceptor blockersFailure hospitalizationCause mortalityOlder patientsDischarge prescriptionsEjection fractionHeart failureAngiotensin-converting enzyme inhibitors/angiotensin II receptor blockersGuidelines-Heart Failure registryRoutine US clinical practiceMedicare beneficiaries ageUS clinical practiceHFrEF medicationsPostdischarge mortalityPostdischarge outcomesClinical outcomesRandomized trialsClinical effectivenessEfficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial
Berg DD, Samsky MD, Velazquez EJ, Duffy CI, Gurmu Y, Braunwald E, Morrow DA, DeVore AD. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. Circulation Heart Failure 2021, 14: e007034. PMID: 33530704, PMCID: PMC7908815, DOI: 10.1161/circheartfailure.120.007034.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAminobutyratesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsCardiotonic AgentsCardiovascular DiseasesChronic DiseaseDrug CombinationsEnalaprilGlomerular Filtration RateHeart FailureHospitalizationHumansHyperkalemiaHypotensionIntensive Care UnitsNatriuretic Peptide, BrainPeptide FragmentsRenal InsufficiencyRiskValsartanConceptsAcute decompensated heart failureSacubitril/valsartanDecompensated heart failureHeart failureCardiovascular deathHigh-risk subpopulationsIndex hospitalizationSymptomatic hypotensionRenal functionSafety outcomesBaseline systolic blood pressureBaseline NT-proBNPPIONEER-HF trialDouble-blind trialHigh-risk patientsGlomerular filtration rateSystolic blood pressureHigh-risk subgroupsRelative risk reductionRisk-benefit profileLow-risk subgroupsHospital initiationInotrope usePIONEER-HFNT-proBNP
2014
Effects of Left Ventricular Assist Device Support on Biomarkers of Cardiovascular Stress, Fibrosis, Fluid Homeostasis, Inflammation, and Renal Injury
Ahmad T, Wang T, O'Brien EC, Samsky MD, Pura JA, Lokhnygina Y, Rogers JG, Hernandez AF, Craig D, Bowles DE, Milano CA, Shah SH, Januzzi JL, Felker GM, Patel CB. Effects of Left Ventricular Assist Device Support on Biomarkers of Cardiovascular Stress, Fibrosis, Fluid Homeostasis, Inflammation, and Renal Injury. JACC Heart Failure 2014, 3: 30-39. PMID: 25447345, DOI: 10.1016/j.jchf.2014.06.013.Peer-Reviewed Original ResearchConceptsVentricular assist device supportC-reactive proteinAssist device supportRenal injuryHeart failureGalectin-3LVAD therapyAmino-terminal pro-B-type natriuretic peptideNeutrophil Gelatinase-Associated Lipocalin LevelsDevice supportPro-B-type natriuretic peptideContinuous-flow LVAD implantationLeft ventricular assist device supportAdvanced heart failureNT-proBNP concentrationsGrowth differentiation factorLipocalin levelsHs-CRPNT-proBNPGDF-15LVAD implantationLVAD placementMedian ageNatriuretic peptideMyocardial recovery